4.6 Article

A Gain-of-Function Variant in Dopamine D2 Receptor and Progressive Chorea and Dystonia Phenotype

Journal

MOVEMENT DISORDERS
Volume 36, Issue 3, Pages 729-739

Publisher

WILEY
DOI: 10.1002/mds.28385

Keywords

hyperkinetic movement disorder; chorea; dystonia; dopamine D2 receptor

Funding

  1. University Medical Center Groningen
  2. University of Groningen [K99DA044287, F31DA047007]
  3. U.S. Public Health Service
  4. Netherlands Organization for Health Research and Development ZonMW Topsubsidie [91218013]
  5. European Fund for Regional Development from the European Union [01492947]
  6. province of Friesland
  7. Dystonia Medical Research Foundation
  8. Stichting Wetenschapsfonds Dystonie Vereniging
  9. Fonds Psychische Gezondheid
  10. Phelps Stichting
  11. US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development [BX003279]
  12. Actelion

Ask authors/readers for more resources

This study described a unique dominantly inherited clinical phenotype in a 4-generation Dutch pedigree, identifying a novel DRD2 gene variant as likely causative. Functional characterization of the variant revealed altered D2 receptor activity in cell models and mouse brain slices, supporting its association with the hyperkinetic movement disorder in the pedigree.
Background We describe a 4-generation Dutch pedigree with a unique dominantly inherited clinical phenotype of a combined progressive chorea and cervical dystonia carrying a novel heterozygous dopamine D2 receptor (DRD2) variant. Objectives The objective of this study was to identify the genetic cause of the disease and to further investigate the functional consequences of the genetic variant. Methods After detailed clinical and neurological examination, whole-exome sequencing was performed. Because a novel variant in the DRD2 gene was found as the likely causative gene defect in our pedigree, we sequenced the DRD2 gene in a cohort of 121 Huntington-like cases with unknown genetic cause (Germany). Moreover, functional characterization of the DRD2 variant included arrestin recruitment, G protein activation, and G protein-mediated inhibition of adenylyl cyclase determined in a cell model, and G protein-regulated inward-rectifying potassium channels measured in midbrain slices of mice. Result We identified a novel heterozygous variant c.634A > T, p.Ile212Phe in exon 5 of DRD2 that cosegregated with the clinical phenotype. Screening of the German cohort did not reveal additional putative disease-causing variants. We demonstrated that the D2(S/L)-(IF)-F-212 receptor exhibited increased agonist potency and constitutive activation of G proteins in human embryonic kidney 239 cells as well as significantly reduced arrestin3 recruitment. We further showed that the D2(S)-(IF)-F-212 receptor exhibited aberrant receptor function in mouse midbrain slices. Conclusions Our results support an association between the novel p.Ile212Phe variant in DRD2, its modified D2 receptor activity, and the hyperkinetic movement disorder reported in the 4-generation pedigree. (c) 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available